Mammography

Take a quick look at Diagnostic Imaging's Top 5 stories of the week.

Race is the most significant contributor to delays with breast cancer diagnosis.

Including a DNA-methylation analysis could improve early diagnosis for BI-RADS 4 patients.

One-click tool is designed to deliver precision consistently across all imaging modalities.

Combination also leads to a reduction in the false-negative rate.

The latest products released on the market for Quarter 2 2021.

Digital breast tomosynthesis offers benefits over mammography, but it is enough to change screening?

Several factors – other than length of clinical experience – weigh into a provider’s interpretive accuracy.

Here's what to expect this week on Diagnostic Imaging.

Primary care providers are less likely to recommend breast MRI for screening high-risk women.

Breast MRI is a good tool for supplemental screening in women who have a personal history of breast cancer.

Cancer screening rates drop more significantly among women in racial and ethnic minority groups, as well as those living in rural locations.

Here's what to expect this week on Diagnostic Imaging.

Meg Eckenroad, Hologic’s vice president of women’s health, discusses the motivation and goals of the new $20-million Project Health Equality.

Dana Bonaminio, M.D., Women’s Imaging National Subspecialty Lead from Radiology Partners, offers tips and guidance on what providers should make sure women know about their breast health.

An effective strategy requires participation by public health advocates, legislators, providers, vendors, and the media.

In collaboration with Black Women’s Health Imperative, National Alliance for Hispanic Health, and RAD-AID, Hologic has launched Project Health Equality.

Here's what to expect this week on Diagnostic Imaging.

Both pre- and post-menopausal women who undergo annual screening mammography have fewer late-stage breast cancer diagnoses, fewer interval cancers, and smaller average tumor size.

Take a quick look at Diagnostic Imaging's Top 5 stories of the week.

Tattoo ink can migrate in female patients, potentially mimicking lymph node findings on breast imaging.

Initial guidance advised these adenopathies would resolve within six weeks. Research and clinical experience shows it’s taking much longer.

The imaging industry has a role to play in bringing about change in screening.

Here's what to expect this week on Diagnostic Imaging.

Research findings show patient age and existing mammogram studies play a role in assessment.